Eyenovia reacquires rights to MicroPine ophthalmic atropine spray in US, Canada
Click Here to Manage Email Alerts
Eyenovia has announced the reacquisition of development and commercialization rights to MicroPine, an investigational 8 µL ophthalmic atropine spray being evaluated for pediatric progressive myopia.
According to a company press release, the reacquisition expands the company’s phase 3 pipeline and commercial capabilities, which include the launch of MydCombi and the anticipated introduction of APP-13007, pending FDA approval. MicroPine would also use Eyenovia’s Optejet dispensing technology.
“With the FDA approval of MydCombi for in-office mydriasis, together with our recent announcement that we in-licensed the U.S. commercial rights to APP-13007 for postocular surgical pain and inflammation from Formosa Pharmaceuticals, our commercialization strategy is accelerating,” Michael Rowe, Eyenovia’s CEO, said in the release. “We believe the addition of MicroPine, if approved, would be highly complementary to these products.”
With the reacquisition, the company plans to accelerate the ongoing CHAPERONE phase 3 trial and work with the FDA to expedite development and registration of MicroPine.
“We believe we are ideally positioned to complete remaining development steps in an expedited and capital efficient manner, and, to that end, we plan to meet with the FDA early this year to align on a path forward for this high-value program,” Rowe said in the release.
Read more about
Click Here to Manage Email Alerts